CDKL2 and breast cancer: Since CD44high/CD24low mesenchymal cells have been linked to increased migration ability and stem cell characteristics in breast cancer [13, 14, 25], we reasoned that the HMLE-CDKL2 phenotypes we observed might merely be due to an increase in the percentage of the CD44high/CD24low subpopulation.